EGFR and breast cancer: Wang F. et al. (2022) identified mitogen-activated protein kinase 1 (MAP2K1), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), recombinant V-Ha-Ras harvey rat sarcoma viral oncogene homolog (HRAS), epidermal growth factor receptor (EGFR), cysteinyl aspartate specific proteinase 3 (Caspase3), and prostaglandin-endoperoxide synthase 2 (PTGS2) as pivotal targets of butyroside anti-breast cancer (BC), suggesting that the PIK3CA-hsa-mir-139-5p-linc01278 and PIK3CA-hsa-mir-375 pathways may be closely related to the mechanism of syringin anti-BC.